Abstract
Physiologically based pharmacokinetic (PBPK) models represent computational technology to characterize drug behavior within the context of detailed human physiology. Today, PBPK is routinely used in drug development and regulatory approval to support decisions on how a medicine can be used under certain clinical conditions. As such, PBPK has the potential to enhance medicine use for populations that are often under-served globally in drug development and clinical care, namely pediatric patients, pregnant and lactating women. To facilitate broader applications of PBPK for these populations, we joined force and organized five hands-on workshops primarily to non-modelers on the principles of PBPK and its potential applications in pediatric and obstetric pharmacology in 2021 and 2022. In this open letter, we report learning objectives and content of such workshops and to highlight the significant value of these educational efforts.
Funder
Bill & Melinda Gates Foundation
Subject
Public Health, Environmental and Occupational Health,Health Policy,Immunology and Microbiology (miscellaneous),Biochemistry, Genetics and Molecular Biology (miscellaneous),Medicine (miscellaneous)
Reference10 articles.
1. Off-label use of medicines in neonates, infants, children, and adolescents: a joint policy statement by the European Academy of Paediatrics and the European society for Developmental Perinatal and Pediatric Pharmacology.;L Schrier;Eur J Pediatr.,2020
2. Pregnant women are still therapeutic orphans.;K Wisner;World Psychiatry.,2020
3. Utilization of Physiologically Based Pharmacokinetic Modeling in Clinical Pharmacology and Therapeutics: an Overview.;C Perry;Curr Pharmacol Rep.,2020
4. Pregnancy- Associated Changes in Pharmacokinetics and their Clinical Implications.;G Koren;Pharm Res.,2018
5. Developmental pharmacology--drug disposition, action, and therapy in infants and children.;G Kearns;N Engl J Med.,2003
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献